phrykt

Oramed Pharmaceuticals Inc. (ORMP): who owns it and who trades it

As of Nov 16, 2026, ORMP insiders reported 4 open-market sales worth $1.2M and no purchases in the last 12 months, with 19% of the sale value made under pre-set 10b5-1 plans. The largest seller was Joshua Hexter (COO & CBO), with $746K. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Oramed Pharmaceuticals

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ORMP

85 funds and institutions reported ORMP shares worth $81.1M at the end of Q2 2026, about 42% of the company. The largest holder is Mercer Global Advisors Inc with 9.4%.

Funds and institutions (13F) 42%Everyone else 58%

10 largest owners, by share of the company

Mercer Global Advisors Inc9.4%
Aquamarine Financial (Cayman) Ltd6.2%
Gem Investment Advisors, LLC4.9%
BlackRock, Inc.4.0%
Murchinson Ltd.3.2%
BML Capital Management, LLC2.1%
Boothbay Fund Management, LLC1.4%
Geode Capital Management, LLC1.2%
Goldman Sachs Group Inc0.6%
State Street Corp0.6%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Mercer Global Advisors Inc3.81M9.42%$18.3M+99%
Aquamarine Financial (Cayman) Ltd2.51M6.21%$12.1M+19%
Gem Investment Advisors, LLC2.00M4.94%$9.6M+22%
BlackRock, Inc.1.61M3.98%$7.7M+1644%
Murchinson Ltd.1.29M3.19%$6.2M-2%
BML Capital Management, LLC866,2692.14%$4.2M-73%
Boothbay Fund Management, LLC578,6381.43%$2.8M-4%
Geode Capital Management, LLC500,6901.24%$2.4M+1962%
Goldman Sachs Group Inc253,2930.63%$1.2MNew
State Street Corp242,1000.60%$1.2MNew
Rathbones Group PLC233,0180.58%$1.1MNo change
Vanguard Portfolio Management LLC229,8820.57%$1.1MNew
Dimensional Fund Advisors LP202,6090.50%$974K+28%
Northern Trust Corp184,9200.46%$889KNew
Renaissance Technologies LLC183,8000.45%$884K+24%
Wells Fargo & Company166,0000.41%$798K+5%
Bank of America Corp150,6940.37%$725K+3%
Strs Ohio133,8000.33%$644KNew
Jane Street Group, LLC113,3490.28%$545K+116%
O'shaughnessy Asset Management, LLC102,9620.25%$495K-12%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, ORMP insiders reported $0 of open-market purchases and $1.2M of sales. 19% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$1.2M
4 trades, 2 people
Sales under a 10b5-1 plan
19%
Share of sale value
Latest trade
Oct 1, 2026
Filed Oct 2, 2026

Purchases and sales by month

$942K$942KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 1, 2026Avraham GabayCFOSale plan20,000$4.51$90.2KForm 4
Oct 1, 2026Joshua HexterCOO & CBOSale plan30,000$4.51$135KForm 4
Jul 1, 2026Joshua HexterCOO & CBOSale137,000$4.46$611KForm 4
Jul 1, 2026Avraham GabayCFOSale73,360$4.51$331KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Joshua HexterCOO & CBO–$746KOct 1, 2026
Avraham GabayChief Financial Officer–$421KOct 1, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ORMP short interest

Low short interest. 3.2% of ORMP shares are sold short: about 1 share in 31. Over the last 12 reports the number of shares short went up 111%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 1.34M ORMP shares were sold short, 3.2% of the shares outstanding, down 7.4% from the report before. At the average daily volume of 118,509 shares, buying them all back would take about 11.3 trading days (days to cover).

Shares short, % of all shares

3.23%May 15Oct 303.80%

Days to cover

11.3May 15Oct 3012.9

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20261.34M3.23%-7%118,50911.3
Oct 15, 20261.45M3.49%+1%139,56710.4
Sep 30, 20261.43M3.45%+10%195,5967.3
Sep 15, 20261.31M3.14%+13%175,9337.4
Aug 31, 20261.15M2.77%+13%269,3524.3
Aug 14, 20261.03M2.47%+23%175,2775.8
Jul 31, 2026835,4932.07%+9%146,7145.7
Jul 15, 2026765,3561.89%-13%306,9232.5
Jun 30, 2026877,8492.17%+54%738,8461.2
Jun 15, 2026570,4471.41%-13%187,6043.0
May 29, 2026659,4641.63%+4%213,8203.1
May 15, 2026635,4311.57%-2%186,0203.4

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Members of Congress who traded ORMP

Since Nov 17, 2024, 1 member of Congress reported 0 purchases and 1 sale of ORMP. The latest was a sale by Brad Knott on Jan 10, 2025, reported Feb 25, 2025.

Purchases 0Sales 1

Reported trades

Trade dateMemberTypeAmountOwnerReportedSource
Jan 10, 2025Brad Knott (R-NC)Sale$15K–$50KSelfFeb 25, 2025Report

Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work

Oramed Pharmaceuticals company events

Oramed Pharmaceuticals filed 10 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Sep 17, 2026.

  1. Sep 17, 2026VoteReported shareholder vote results. Filing
  2. Jun 30, 2026AnnouncementThe Company and Scilex Holding Company agreed to a further extension of the outstanding payment obligations, including the outstanding principal amount, any accrued interest thereon and any other fees, owed by Scilex to the Company pursuant to (i) the Senior Secured Promissory Note dated September… Filing
  3. Mar 31, 2026DealThe information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly… Filing
  4. Feb 20, 2026AgreementOramed Pharmaceuticals Inc. entered into a Warrant Agreement with Scilex Holding Company. Filing
  5. Jan 14, 2026AgreementOramed Pharmaceuticals Inc. entered into that certain Share Purchase Agreement, by and among the Company, Lifeward Ltd. and Oratech Pharma, Inc., the Company’s wholly-owned subsidiary. Filing
  6. Jan 7, 2026AnnouncementOramed Pharmaceuticals Inc. issued a press release announcing it has received an $18 million payment from Scilex Holdings Inc., representing full satisfaction of obligations under the Option Agreement. Filing
  7. Dec 31, 2025LeadershipThe board of directors of Oramed Pharmaceuticals Inc. received notice of Leonard Sank’s intention to resign from the Board, effective as of January 1, 2026. Filing
  8. Dec 31, 2025AnnouncementAs previously disclosed in its Current Report on Form 8-K filed with the Securities and Exchange Commission on July 23, 2025, on July 22, 2025, Oramed Pharmaceuticals Inc. entered into an Option Agreement for the Repurchase of Warrants with Scilex Holding Company pursuant to which, among other… Filing
  9. Nov 17, 2025ResultsReleased financial results. Filing
  10. Nov 17, 2025AgreementThe Board of Directors of Oramed Pharmaceuticals Inc. declared a dividend of one common stock purchase right (a “Right”) for each outstanding share of common stock, par value $0.012 per share, of the Company. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Oramed Pharmaceuticals financials

Famous investors that hold ORMP

2 of the 50 well-known investors we track reported holding ORMP in their latest 13F filing. The largest position is Jim Simons's, worth $1.4M.

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 2026294,268$1.4M0.0%+60%
Ken Griffin · Citadel AdvisorsQ3 202659,844$279K0.0%+44%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named ORMP in the last 120 days.

FiledHolderFormStake
Nov 13, 2026Aquamarine Financial (Cayman) Ltd13G/A6.4%
Nov 13, 2026Aquamarine Financial (Cayman) Ltd13G/A6.4%

Questions about Oramed Pharmaceuticals Inc. (ORMP) stock

Who owns the most ORMP stock?

The largest reported owner of Oramed Pharmaceuticals Inc. (ORMP) is Mercer Global Advisors Inc, with 9.4% of the company. In total, 85 funds and institutions reported holding ORMP at the end of Q2 2026, together about 42% of the shares. See the largest owners.

Are ORMP insiders buying or selling?

In the last 12 months, ORMP insiders reported no open-market purchases and 4 sales worth $1.2M. The latest trade was on Oct 1, 2026. See every trade.

What is the short interest in ORMP?

As of Oct 30, 2026, 1.34M ORMP shares were sold short, 3.2% of the shares outstanding, down 7.4% from the report before. At the average daily volume of 118,509 shares, buying them all back would take about 11.3 trading days (days to cover). See the history.

Have members of Congress traded ORMP?

Yes. 1 member of Congress reported 0 purchases and 1 sale of ORMP since Nov 17, 2024. The latest was reported on Feb 25, 2025. See the trades.

Which famous investors hold ORMP?

2 of the 50 well-known investors we track reported ORMP in their latest 13F filing, including Jim Simons, Ken Griffin. The largest position is worth $1.4M. See all holders.

Executive pay

Oramed Pharmaceuticals's chief executive was paid a total of $4.8M for the year ended Dec 31, 2025, up 128% from $2.1M the year before. In the last 12 months, Oramed Pharmaceuticals's executives and directors bought no stock on the open market and sold $1.2M.

Chief executive, total pay$4.8MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$4.8MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$2MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.